Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.

Ronald J Ellis, Will Toperoff, Florin Vaida, Geoffrey van den Brande, James Gonzales, Ben Gouaux, Heather Bentley & J Hampton Atkinson

Neuropsychopharmacology volume 34, pages 672–680 (2009)

Baseado em evidências científicas e não em achismo! Conheça mais sobre o tema.

Despite management with opioids and other pain modifying therapies, neuropathic pain continues to reduce the quality of life and daily functioning in HIV-infected individuals. Cannabinoid receptors in the central and peripheral nervous systems have been shown to modulate pain perception. We conducted a clinical trial to assess the impact of smoked cannabis on neuropathic pain in HIV. This was a phase II, double-blind, placebo-controlled, crossover trial of analgesia with smoked cannabis in HIV-associated distal sensory predominant polyneuropathy (DSPN). Eligible subjects had neuropathic pain refractory to at least two previous analgesic classes; they continued on their prestudy analgesic regimens throughout the trial. Regulatory considerations dictated that subjects smoke under direct observation in a hospital setting. Treatments were placebo and active cannabis ranging in potency between 1 and 8% Delta-9-tetrahydrocannabinol, four times daily for 5 consecutive days during each of 2 treatment weeks, separated by a 2-week washout.

Link para o Artigo:

69 visualizações0 comentário

© 2019 Aliança Verde – Instituto de Pesquisas Científicas e Medicinais das Plantas - Todos os direitos reservados

Aliança Verde

Somos uma associação civil, de direito privado, sem fins lucrativos, formado por pacientes medicinais de Cannabis, médicos, profissionais diversos e pesquisadores.


Site informativo para pessoas que buscam  tratamento medicinal digno com a cannabis.

Nossos Parceiros
revista ganja.png